Borderline ovarian tumors: outcomes of fertility sparing surgery

Aim: Borderline ovarian tumors(BOT) account for ten to 20 percent of all epitelial ovarian carcinomas and often occur in reproductive ages. The aim of this study was to evaluate the clinical and reproductive outcomes of patients who were diagnosed with BOT and underwent fertility sparing surgery. Materials and Methods: Patients younger than 40 years who underwent fertility sparing surgery for BOT from 2004 to 2012 were reviewed retrospectively and were evaluated according to the reproductive and clinical outcomes. Results: Twenty-eight patients younger than 40 years with BOT underwent fertility sparing surgery. Median follow up time was 42 ± 28.1 months. During the follow up period, two patients (7.1%) developed recurrence at 35 and 36 months, respectively. Five (17.9%) out of 28 patients became pregnant during the follow up period. Conclusion: Fertility sparing surgery should be the first choice for the treatment of BOT in patients who wish to preserve fertility.

Borderline ovarian tumors; Fertility sparing surgery; Pregnancy.

[1] Sherman M.E., Mink P.J., Curtis R., Cote T.R., Brooks S., Hartge P., Devesa S.: “Survival among women with borderline ovarian tumors and ovarian carcinoma:a population-based analysis”. Cancer, 2004, 100, 1045.

[2] Park J.Y., Kim D.Y., Kim J.H., Kim Y.M., Kim Y.T., Nam J.H.: “Surgical management of borderline ovarian tumors:The role of fertility-sparing surgery”. Gynecol. Oncol., 2009, 113, 75.

[3] Song T., Choi C.H., Park H.S., Kim M.K., Lee Y.Y., Kim T.J. et al.: “Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes”. Int. J. Gynecol. Cancer, 2011, 21, 640.

[4] Fain-Kahn V., Poirot C., Uzan C., Prades M., Gouy S., Genestie C. et al.: “Feasibility of ovarian cryopreservation in borderline ovarian tumours”. Hum. Reprod., 2009, 24, 850.

[5] Viganò R., Petrone M., Pella F., Rabaiotti E., De Marzi P., Mangili G.: “Surgery in advanced borderline tumors”. Fertil. Steril., 2010, 94, 1163.

[6] Romeo M., Pons F., Barretina P., Radua J.: “Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor”. World J. Surg. Oncol., 2013, 11, 13.

[7] Morice P.: “Borderline tumours of the ovary and fertility”. Eur. J. Cancer, 2006, 42, 149.

[8] Romagnolo C., Gadducci A., Sartori E., Zola P., Maggino T.: “Management of borderline ovarian tumors: results of an Italian multi-center study”. Gynecol. Oncol., 2006, 101, 255.

[9] Poncelet C., Fauvet R., Boccara J., Daraï E.: “Recurrence after cystectomy for borderline ovarian tumors: results of a French multi-center study”. Ann. Surg. Oncol., 2006, 13, 565.

[10] Ren J., Lou J.Y., Liu H., Wang P., Zhang J.W., Yang K.X. et al.: “Clinicopathologic features of 234 cases with borderline ovarian tu-mors”. Zhonghua Fu Chan Ke Za Zhi, 2009, 44, 116.

[11] Ewald-Riegler N., du Bois O., Fisseler-Eckhoff A., Kommoss F., Harter P., Traut A. et al.: “Borderline tumors of the ovary: clinical course and prognostic factors”. Onkologie, 2012, 35, 28.

[12] Fauvet R., Brzakowski M., Morice P., Resch B., Marret H., Graesslin O.: “Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study”. Ann. Oncol., 2012, 23, 1481.

[13] Suh-Burgmann E.: “Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study”. Gynecol. Oncol., 2006, 103, 841.